COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

On Thursday, Novavax Inc. NVAX reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million.Higher product sales for the first quarter of 2025 were primarily due to $603 million of revenue recognized with the termination of two Advance Purchase Agreements (APA) and related to cash received in prior years. $45 million of Licensing, Royalties, & Other Revenue in the first quarter of 2025 was higher than the prior year due to $40 million of San ...